psychiatry & behavioral healthquestionnaire

PHQ-9 (Patient Health Questionnaire-9)

The PHQ-9 is a 9-item self-report questionnaire that scores each of the DSM criteria for major depressive disorder on a 0–3 severity scale. It is the most widely validated depression screening and severity monitoring tool in primary care worldwide. Total scores range from 0 to 27.

questionnaire

⚠ Any positive response to this item requires immediate clinical assessment for suicidal risk.

when to use

Use for depression screening in adults in primary care, outpatient, and inpatient settings. Suitable for initial detection, severity grading, and serial monitoring of treatment response (repeat every 2–4 weeks during active treatment). Endorsed by NICE, USPSTF, and multiple international guidelines for routine depression screening. Also used in research as a standardised outcome measure.

when not to use

The PHQ-9 is a screening and severity measure, not a diagnostic tool in isolation — a positive screen requires clinical interview to confirm diagnosis. Not validated for children under 12 (use PHQ-A for adolescents). Scores may be elevated by somatic symptoms from medical illness (e.g., fatigue from anaemia, sleep disturbance from pain) — clinical judgement is required to differentiate. The PHQ-9 does not assess bipolar disorder — consider the MDQ if bipolarity is suspected before initiating antidepressants.

clinical pearls

  • Item 9 (suicidal ideation) is the single most important item clinically. ANY positive response (score ≥1 on item 9) requires direct clinical follow-up with a safety assessment — do not rely on the total score alone.
  • A score of ≥10 is the standard screening threshold for probable major depression (88% sensitivity, 88% specificity), but this is a screening cut-off, not a diagnosis. Always conduct a clinical interview to confirm.
  • The PHQ-9 is sensitive to change and is excellent for monitoring treatment response. A ≥5-point decrease is considered a clinically meaningful improvement. Failure to achieve at least a 50% reduction in PHQ-9 score by 6–8 weeks should prompt treatment review.
  • The first two items (Q1: anhedonia, Q2: depressed mood) form the PHQ-2, which can be used as an ultra-brief initial screen. A PHQ-2 score ≥3 should prompt completion of the full PHQ-9.
  • The PHQ-9 items reflect DSM criteria, so the questionnaire can also be used diagnostically: if 5+ items are scored ≥2 ('more than half the days'), and one of the first two items (depressed mood or anhedonia) is among them, this corresponds to the symptom count threshold for major depressive disorder. However, clinical interview remains the gold standard for diagnosis.